Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa
Research output: Contribution to conference › Other › peer-review
Standard Standard
Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa. / Culeddu, Giovanna; Brogan, Paul A.; Hughes, Dyfrig.
2021. Health Technology Assessment International 2021.
2021. Health Technology Assessment International 2021.
Research output: Contribution to conference › Other › peer-review
HarvardHarvard
Culeddu, G, Brogan, PA & Hughes, D 2021, 'Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa', Health Technology Assessment International 2021, 19/06/21 - 23/06/21.
APA
Culeddu, G., Brogan, P. A., & Hughes, D. (2021). Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa. Health Technology Assessment International 2021.
CBE
Culeddu G, Brogan PA, Hughes D. 2021. Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa. Health Technology Assessment International 2021.
MLA
Culeddu, Giovanna, Paul A. Brogan, and Dyfrig Hughes Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa. Health Technology Assessment International 2021, 19 Jun 2021, Other, 2021.
VancouverVancouver
Culeddu G, Brogan PA, Hughes D. Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa. 2021. Health Technology Assessment International 2021.
Author
RIS
TY - CONF
T1 - Cost-Effectiveness Analysis of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in Childhood Polyarteritis Nodosa
AU - Culeddu, Giovanna
AU - Brogan, Paul A.
AU - Hughes, Dyfrig
N1 - Oral Presentation
PY - 2021
Y1 - 2021
M3 - Other
T2 - Health Technology Assessment International 2021
Y2 - 19 June 2021 through 23 June 2021
ER -